



## AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

May 7, 2026

MENLO PARK, Calif.--(BUSINESS WIRE)--May 7, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026 at 4:00 PM ET, and members of management will be available for 1x1 meetings.

A webcast can be accessed on the Investors section of the AN2 Therapeutics website at [www.an2therapeutics.com](http://www.an2therapeutics.com). An archived replay will be available for at least 30 days following the presentation.

### About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260507382103/en/): <https://www.businesswire.com/news/home/20260507382103/en/>

### COMPANY CONTACT:

Lucy O. Day  
Chief Financial Officer  
[l.day@an2therapeutics.com](mailto:l.day@an2therapeutics.com)

### INVESTOR AND MEDIA CONTACT:

Anne Bowdidge  
[ir@an2therapeutics.com](mailto:ir@an2therapeutics.com)

Source: AN2 Therapeutics, Inc.